Andy Cohen TRT: The Ethics of Celebrity Prescription Disclosure

What Andy Cohen Has Said About TRT

Cohen has addressed his testosterone use in at least two notable public settings. He mentioned it during an appearance on the "Siriusly Sinatra" channel and discussed related health optimization topics on his own "Andy Cohen Live" SiriusXM show. He has described TRT as part of a broader approach to maintaining energy, mood, and physical wellness as he has aged into his mid-50s.

His statements fall squarely into the category of voluntary personal disclosure rather than promotional activity. No commercial relationship with a pharmaceutical manufacturer has been publicly reported in connection with these comments.

What Cohen Did Not Say

Cohen has not claimed TRT cured a specific disease, and he has not urged listeners to seek prescriptions without medical evaluation. That distinction is clinically meaningful. A public figure saying "I use this and feel better" carries very different weight from "you should use this." The former is personal testimony; the latter approaches unlicensed medical advice.

Why the Specifics of His Disclosure Matter

When a celebrity volunteers a prescription medication name rather than a vague reference to "hormones" or "optimization," the disclosure becomes useful raw material for public health education. Audiences can search the actual drug class, find clinical evidence, and ask their own physicians informed questions. Specificity, in that context, reduces the chance of misinformation filling the gap.

A three-tier framework helps evaluate any celebrity Rx disclosure:

1. Factual accuracy. Did the celebrity describe the treatment correctly? Cohen's description of TRT as a medically supervised hormone protocol is consistent with how the Endocrine Society defines it.
2. Appropriate caveats. Did the celebrity note that a physician must evaluate and prescribe? Cohen's public comments have generally referenced working with a doctor.
3. Commercial interest. Does the celebrity have a financial relationship with the manufacturer or a prescribing platform? No such relationship has been reported for Cohen's TRT statements.

What Is TRT and Who Qualifies?

Testosterone replacement therapy is the administration of exogenous testosterone to men whose endogenous production has fallen below the threshold needed to maintain normal physiological function. The Endocrine Society defines male hypogonadism as a total testosterone level below 300 ng/dL combined with clinical symptoms, and their 2018 Clinical Practice Guideline states: "We recommend making a diagnosis of androgen deficiency only in men with consistent symptoms and signs and unequivocally low serum testosterone levels." [1]

Symptoms that prompt evaluation include low libido, reduced muscle mass, increased fat mass, fatigue, depressed mood, and impaired concentration. These overlap considerably with normal aging, which is exactly why laboratory confirmation is required before prescribing.

Prevalence of Hypogonadism

Population data from the European Male Ageing Study, published in the Journal of Clinical Endocrinology and Metabolism, estimated that late-onset hypogonadism affects approximately 2.1% of men aged 40 to 79, rising steeply with age and comorbid conditions such as obesity and type 2 diabetes. [2] A separate analysis using NHANES data found that roughly 20% of men over 60 have total testosterone below 300 ng/dL. [3]

FDA-Approved Delivery Forms

The FDA has approved multiple testosterone formulations. [4] These include:

• Intramuscular or subcutaneous injections (testosterone cypionate, testosterone enanthate)
• Topical gels (AndroGel, Testim, Vogelxo)
• Transdermal patches (Androderm)
• Subcutaneous pellets (Testopel)
• Nasal gel (Natesto)
• Buccal systems (Striant)

Formulation choice depends on patient preference, absorption variability, skin sensitivity, and cost. Injections remain the most cost-effective option and allow direct serum-level monitoring tied to dosing intervals.

Clinical Evidence Supporting TRT in Hypogonadal Men

The largest cardiovascular safety study of TRT to date is the TRAVERSE trial, a randomized, double-blind, placebo-controlled study that enrolled 5,246 men aged 45 to 80 with hypogonadism and pre-existing or high risk of cardiovascular disease. [5] Participants received testosterone gel 1.62% or placebo for a mean of 33 months.

The primary cardiovascular endpoint (major adverse cardiac events) occurred in 7.0% of the testosterone group versus 7.3% in the placebo group, meeting the pre-specified non-inferiority margin. The trial also found a higher incidence of atrial fibrillation (3.5% vs. 2.4%), pulmonary embolism (0.9% vs. 0.5%), and acute kidney injury in the testosterone arm, all of which represent real clinical considerations that prescribers must discuss with patients. [5]

The Testosterone Trials (TTrials)

The Testosterone Trials, a coordinated set of seven placebo-controlled trials in 788 men aged 65 and older with low testosterone (below 275 ng/dL), showed that one year of testosterone treatment improved sexual function, physical function modestly, and bone mineral density. [6] The sexual function trial found a mean increase of 1.2 points on the Deyo-Dworkin scale compared with placebo (P<0.001). [6] Cognitive function did not improve significantly at 12 months.

What the Evidence Does Not Show

TRT has not demonstrated mortality benefit in any completed randomized trial. The Endocrine Society guideline explicitly discourages TRT in men without confirmed biochemical hypogonadism. [1] Anyone citing Andy Cohen's public statements as a reason to start testosterone without lab work and physician evaluation is misreading both the celebrity's comments and the underlying clinical literature.

The Ethics of Celebrity Prescription Disclosure

Why It Is Different From Ordinary Health Talk

A private citizen discussing their medications with friends carries negligible public health consequences. A media personality with millions of listeners carries something closer to a platform effect. Research on health information-seeking behavior consistently shows that celebrity health disclosures shift audience interest toward the disclosed condition or treatment. [7]

The Angelina Jolie effect on BRCA testing is the most studied example. After Jolie published her 2013 New York Times essay about her prophylactic mastectomy, BRCA referrals and testing rates increased significantly across multiple health systems, a pattern documented in published literature. [8] TRT disclosure by a well-known male figure could plausibly have a similar, smaller-scale effect on men seeking testosterone testing.

That influence is not inherently harmful. Men with undiagnosed hypogonadism who seek testing because a public figure normalized the conversation represent a genuine public health benefit. The risk arises when disclosure is incomplete, inaccurate, or commercially motivated.

The Commercial Interest Problem

Direct-to-consumer testosterone prescribing platforms have expanded dramatically since 2018. Several operate with minimal clinical oversight, using brief asynchronous questionnaires to justify prescriptions without physical examination or verified lab values. The FTC has taken enforcement action against some telehealth platforms for deceptive marketing of prescription drugs, and the FDA has issued warnings about testosterone products marketed without adequate labeling. [9]

When a celebrity's disclosure does not include the words "my doctor ordered labs first," audiences absorbing that message may seek TRT through the path of least resistance, which increasingly means a low-oversight online platform. That gap between celebrity testimony and clinical reality is where ethical risk concentrates.

Informed Advocacy vs. Implicit Endorsement

The Endocrine Society states in its patient resources that testosterone therapy "should only be initiated after a thorough medical evaluation that includes at least two morning testosterone measurements." [1] A celebrity who mentions TRT without mentioning labs and clinical evaluation is not necessarily acting unethically, but the disclosure is incomplete in a clinically meaningful way.

Cohen's publicly available statements have generally included references to medical supervision. That puts his disclosures in a more responsible category than many influencer-driven testosterone promotions circulating on social media, where "I feel amazing" testimonials often appear without any reference to diagnosis, dosing, or monitoring.

What a Responsible Clinical Workup Looks Like

Before any clinician prescribes TRT, the Endocrine Society guideline recommends confirming hypogonadism with at least two morning total testosterone measurements, ideally collected between 7 a.m. And 10 a.m. When levels peak. [1] A single low result is insufficient for diagnosis.

Laboratory Panel Checklist

A thorough baseline workup typically includes:

• Total testosterone (morning, fasting preferred)
• Free testosterone (calculated or by equilibrium dialysis)
• Luteinizing hormone (LH) and follicle-stimulating hormone (FSH) to differentiate primary from secondary hypogonadism
• Complete blood count (hematocrit is a key safety marker during treatment)
• Prostate-specific antigen (PSA) in men aged 40 and older
• Estradiol
• Metabolic panel and lipid panel

Contraindications

Absolute contraindications to TRT include breast cancer, prostate cancer, hematocrit above 54%, severe untreated obstructive sleep apnea, and uncontrolled heart failure. [1] Men with any of these conditions should not receive testosterone regardless of serum levels.

Monitoring During Treatment

After initiating TRT, the Endocrine Society recommends checking testosterone levels, hematocrit, and PSA at 3 to 6 months, then annually. [1] The TRAVERSE trial's finding of higher pulmonary embolism rates (0.9% vs. 0.5%) underscores why hematocrit monitoring is not optional. [5] Rising hematocrit above 54% requires dose reduction or discontinuation.

Why the Media-Medicine Boundary Matters for GLP-1 and Beyond

TRT is not the only treatment category where celebrity disclosure shapes patient behavior. GLP-1 receptor agonists such as semaglutide (Ozempic, Wegovy) saw prescription demand surge in 2022 and 2023 partly because of celebrity discussion on social media and in entertainment journalism. The STEP-1 trial (N=1,961) showed that semaglutide 2.4 mg produced 14.9% mean body weight loss at 68 weeks versus 2.4% with placebo. [10] That is a real, large effect. But the surge in off-label prescribing for cosmetic weight loss created shortages that affected patients with type 2 diabetes who depended on semaglutide therapeutically.

The pattern is consistent: celebrity disclosure accelerates demand without educating audiences about appropriate patient selection, contraindications, or the difference between on-label and off-label use.

A Standard for Responsible Disclosure

No federal law requires a non-medical public figure to provide clinical context when discussing their own prescriptions. The ethical standard is therefore voluntary. A disclosure is more responsible when it includes:

1. Confirmation that a licensed clinician made the diagnosis
2. Reference to the diagnostic criteria or lab work involved
3. Acknowledgment that results vary and that the treatment is not appropriate for everyone
4. Absence of commercial incentive (or, if commercial, explicit disclosure of that relationship)

Cohen's statements about TRT appear to meet criteria one and four based on available public record. Whether they fully meet criteria two and three depends on the specific interview context.

The Broader Field of Male Hormone Health Literacy

Research on health literacy consistently shows that men engage less frequently with preventive healthcare than women. A 2020 analysis in the American Journal of Men's Health found that men were significantly less likely to have had a preventive care visit in the prior 12 months compared with women, even after controlling for insurance status and income. [11]

Public figures who discuss their own hormone testing and treatment normalize the idea that men should seek medical evaluation for symptoms they might otherwise dismiss as "just getting older." That normalization has measurable value. The risk is that disclosure without clinical context points men toward prescribing mills rather than toward internists, urologists, or endocrinologists who can do a thorough evaluation.

The Role of Telehealth

Telehealth TRT prescribing has made diagnosis and treatment genuinely more accessible for men in rural areas or those who face barriers to in-person care. A 2022 study in JAMA Internal Medicine found that telehealth expanded access to specialty-equivalent care for chronic conditions in underserved areas. [12] Accessibility is a real benefit. The problem is not telehealth itself but the subset of telehealth platforms that bypass the diagnostic rigor the Endocrine Society requires.

A well-run telehealth TRT program orders lab work before prescribing, verifies results, checks for contraindications, and schedules follow-up monitoring. That process can happen entirely remotely. The absence of that process, not the remote delivery model, is what creates risk.

Practical Guidance for Men Who Heard About TRT From a Public Figure

If Cohen's disclosures, or anyone else's, prompted interest in TRT, the appropriate next step is a conversation with a primary care physician, urologist, or endocrinologist, not a direct-to-consumer platform visit.

Request a morning total testosterone test and a follow-up interpretation with a clinician who will also assess LH, FSH, hematocrit, and PSA. If total testosterone comes back below 300 ng/dL on two separate occasions and you have consistent symptoms, you are a potential candidate for treatment under Endocrine Society criteria. [1]

If testosterone is in the normal range (300 to 1,000 ng/dL), symptoms like fatigue, low mood, and reduced libido warrant evaluation for other causes: sleep apnea, thyroid dysfunction, depression, metabolic syndrome, or medication side effects. Testosterone therapy in eugonadal men has not been shown to produce symptom benefit exceeding placebo in controlled trials, and it carries the cardiovascular and hematologic risks documented in TRAVERSE. [5]

The right question to ask a clinician is not "can I get TRT?" It is "what is my testosterone level, and if it is low, what is causing it?"